Polsinelli has established itself as a major influential law and public policy firm in the nation’s capital since opening its Washington, D.C., office in 2005. Our bipartisan team is comprised of former executive branch officials and senior congressional staff. We advise clients on appropriations, budget, health care, education, immigration and tax policy, as well as First Amendment advertising and media law. The Federal Public Policy practice represents a diverse range of clients that include Fortune 500 corporations, national broadcast and cable networks, food manufacturers, pharmaceutical companies, medical device manufacturers, national construction firms, along with businesses and executives who need our guidance in antitrust, white-collar crime and regulatory litigation.

Our Federal Public Policy practice has directed multiple efforts to defeat federal government proposals to tax or regulate the content of commercial advertising. They have secured government approval of new and innovative medicines and medical devices, and they have stopped a national tax on the sale of broadcast stations.

Our State Public Policy professionals are located in a number of Polsinelli offices, including the capital city of Jefferson City, Missouri. Together, they bring decades of experience in state and local regulatory and administrative law matters, regulation of corporate and business and utility activities in insurance, energy, transportation, health care, construction, telecommunications, pharmaceuticals, consumer product regulation, economic development and gaming businesses.

Our range of services include: 

Related Capabilities
Public Policy - Health CareEnergyImmigration & Global MobilitySports & Entertainment
Publications
All Publications
Beyond the Pump: The Iran War’s Adverse Impact on U.S. Health Care
Key Takeaways The closure of the Strait of Hormuz following the U.S.-Iran conflict is disrupting global health care supply chains and increasing costs for critical medical products. Shortages and delays are already affecting pharmaceuticals, MRI-related helium supplies and cold-chain products. The disruptions create operational and financial pressure for health care providers that depend on imported drugs, medical equipment and time-sensitive supplies. Rising freight, fuel and insurance costs are contributing to higher prices and longer lead times across multiple product categories. Health care organizations should closely monitor supply availability, transportation delays and pricing volatility tied to the ongoing conflict and shipping restrictions. Providers may need to evaluate inventory levels, supplier diversification and contingency planning for critical medical inputs. Since the beginning of the United States’
Read More
Election Year Politics and Policy at CMMI: What Stakeholders Can Expect
Key Takeaways CMS’ Innovation Center is accelerating new payment and care delivery models as the Trump administration uses CMMI to advance health policy priorities. Current models target areas such as chronic care, behavioral health, drug pricing and value-based care. CMMI remains a powerful policy vehicle, but its recent pace has drawn renewed scrutiny over cost savings, scale and taxpayer value. That debate could shape oversight, legislation and expectations for how future models are designed and evaluated. Health care stakeholders should continue tracking CMMI closely as participation opportunities expand and mandatory models create new operational demands. Organizations should assess where engagement, compliance planning or advocacy may be needed as models evolve. The Centers for Medicare & Medicaid Services (CMS) is currently pursuing approximately 35 models
Read More